BNTX: BioNTech Inc. Sotuvga nisbatan narx
BioNTech SE (BNTX) keng ko'lamli ilmiy investitsiyalar va ulkan maqsadlar orqali yetakchi immunologlarni jalb qilmoqda. Savdo daromadiga nisbatan narx koeffitsiyenti ushbu strategiyani tasdiqlaydi, bunda 7.50 qiymati joriy ko'rsatkichni aks ettiradi. Rahbarlik saraton va viruslarga qarshi kurashish uchun moslashuvchan mRNA platformasi orqali amalga oshirilmoqda, ta'minot ishonchliligi esa optimallashtirilgan sovuq zanjir logistikasi bilan kafolatlanadi.
BioNTech Group (BNTX) kompaniyasi koʻrsatkichlari kesimi va tahlili
- aksiya narxi va konsensus maqsadli narx:
- bozor kapitallashuvi haqida ma'lumot:
- aksiyadorlik kapitalining balans qiymati ma'lumotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning kapitalga nisbati BioNTech SE|BNTX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi BioNTech Pharma|BNTX - Kompaniyaning umumiy qarzi|Qarzning balans kapitaliga nisbati BioNTech Group|BNTX - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz BioNTech|Tezkor likvidlik ko‘rsatkichi biontech.de
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
BNTX - Sof foyda|Kutilayotgan sof daromad BioNTech SE|BNTX - Narx-foyda koeffitsiyenti|Kelajakdagi narx-foyda multiplikatori BioNTech Inc.|BNTX - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati BioNTech Group|BNTX - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda BioNTech|BNTX - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun foydaning yillik o'sishi biontech.de|BNTX - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foydaning prognoz qilingan o'sish sur'ati BioNTech SE
- emitentning tushumi va sotuvlari tafsilotlari:
Kompaniyaning jamlanma tahliliyoti:biontech.de
Tijoriy dori portfelining yo'qligi va qimmat R&D loyihalariga bog'liqlik BioNTech SE (BNTX) kompaniyasini bozor narxlariga ta'sir qilish imkoniyatidan mahrum qiladi. Ushbu kapitalizatsiyaning daromadga nisbati joriy savdolardan yuqori bo'lgan premiumni o'lchaydi, bu esa investorlarga kelajakdagi kutuvlar uchun haddan tashqari ko'p to'lash xavfini baholash imkonini beradi; shu bilan birga, ko'rsatkichlarning shishirilgan qiymatlari yangi o'sish drayverlari yo'qligida aktiv qiymatining potentsial korreksiyasi haqida signal beradi.
Raqobatdosh kompaniyalar
argenx.com - Kapitalizatsiya va daromad nisbati|P/S multiplikatori ABVX (Abivax S.A.)|ADMA Biologics Inc (ADMA) - Sotuvga nisbatan narx|Protagonist Therapeutics Inc - P/S multiplikatori|IMVT: Narxning daromadga nisbati|KNSA: P/S multiplikatori|GRFS - Narx/daromad koeffitsiyenti|Narxning daromadga nisbati Adaptive Biotechnologies Corporation|Sotuvga nisbatan narx Celldex Therapeutics Inc CLDX|Narxning daromadga nisbati Aurinia Pharma (AUPH)|BioCryst Corp - Kapitalizatsiya va daromad nisbati|Vera Therapeutics, Inc. - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati DNTH (dianthustx.com)|Pharvaris - P/S multiplikatori|Sotuvga nisbatan narx AbCellera Biologics Inc.|TRML: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Precigen Corp|PHAR (Pharming Group N.V.) - P/S multiplikatori|NKTR: Bozor kapitallashuvining daromadga nisbati|Kapitalizatsiyaning daromadga nisbati UPB (Upstream Bio)|ZBIO (Zenas Bio) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Immunome Corp IMNM|Narx/daromad koeffitsiyenti Gossamer Bio Corp. (GOSS)|KalVista Pharmaceuticals - P/S multiplikatori|Sotuvga nisbatan narx septerna.com|PVLA: P/S multiplikatori|SVRA (Savara Inc) - Narxning daromadga nisbati|Narxning daromadga nisbati Rigel Pharmaceuticals Inc|Kapitalizatsiya va daromad nisbati ANAB (AnaptysBio Inc.)|Kapitalizatsiyaning daromadga nisbati ATXS (Astria Therapeutics)|Kapitalizatsiyaning sotish hajmiga nisbati ENGN|RAPT Therapeutics - Kapitalizatsiyaning daromadga nisbati|JBIO: Kapitalizatsiya va daromad nisbati|ACRS - Narxning daromadga nisbati|Narxning sotuvga nisbati KYTX|TLSA: P/S multiplikatori|cabalettabio.com - Bozor kapitallashuvining daromadga nisbati|VTYX (Ventyx Biosciences, Inc.) - P/S multiplikatori|P/S multiplikatori Theratechnologies, Inc.|Narxning daromadga nisbati Avalo Therapeutics Inc. (AVTX)|ELDN (Eledon Pharmaceuticals, Inc) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Agenus AGEN|CLYM - Kapitalizatsiyaning daromadga nisbati|Zura Bio - P/S multiplikatori|ATYR - P/S multiplikatori|ADAG (adagene.com) - Kapitalizatsiyaning daromadga nisbati|Ikena Oncology - Bozor kapitallashuvining daromadga nisbati|STTK (Shattuck Labs Inc) - P/S multiplikatori|Equillium Bio (EQ) - Narx/daromad koeffitsiyenti|Narxning daromadga nisbati Connect Biopharma (CNTB)|Kapitalizatsiyaning daromadga nisbati immunic-therapeutics.com IMUX|Narxning daromadga nisbati Atara Bio ATRA|IFRX - Kapitalizatsiyaning daromadga nisbati|XFOR: Kapitalizatsiyaning daromadga nisbati|ACET - P/S multiplikatori|celularity.com (CELU) - Narxning daromadga nisbati|Kapitalizatsiya va daromad nisbati INMB|BRNS (Barinthus Bio) - P/S multiplikatori|Sotuvga nisbatan narx Kezar Life Sciences Inc KZR|P/S multiplikatori SABS|Narxning daromadga nisbati AKTX (akaritx.com)|P/S multiplikatori ENLV (Enlivex Therapeutics Ltd.)|Narx/daromad koeffitsiyenti Q32 Bio Inc (QTTB)|GOVX - Narxning daromadga nisbati|Sotuvga nisbatan narx Edesa Biotech Corp|iBio, Inc. (IBIO) - Narxning daromadga nisbati|Kapitalizatsiya va daromad nisbati CARM|Kapitalizatsiyaning daromadga nisbati XTLB|BOLT (Bolt Bio) - Kapitalizatsiyaning sotish hajmiga nisbati|P/S multiplikatori HCWB|APVO - Sotuvga nisbatan narx|P/S multiplikatori AIM (AIM ImmunoTech Inc.)|ADTX - Kapitalizatsiyaning daromadga nisbati|GRI Bio - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati XRTX (XORTX Therapeutics Inc)|HIND (ReShape Lifesciences) - Kapitalizatsiyaning daromadga nisbati|Revelation Biosciences Corp - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Indaptus Therapeutics|scinai.com (SCNI) - Narx/daromad koeffitsiyenti|P/S multiplikatori CALI|AFMD - Sotuvga nisbatan narx|P/S multiplikatori ALLK (Allakos)|HOOKIPA Pharma, Inc. - Narxning daromadga nisbati|IGMS - Narxning daromadga nisbati|ITOS (iteostherapeutics.com) - Kapitalizatsiya va daromad nisbati|OCEA (Ocean Biomedical) - Kapitalizatsiyaning daromadga nisbati|TCBP: Kapitalizatsiyaning sotish hajmiga nisbati|Kapitalizatsiyaning daromadga nisbati THRD
